Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta
TORONTO, June 1, 2020 /CNW/ - Mitsubishi Tanabe Pharma Corporation Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA® (edaravone) is now listed on the Alberta Drug Benefit List formulary (special authorization). RADICAVA is an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neurodegenerative, fatal disease that affects the nerve cells in the brain and spinal cord that control voluntary muscle movement.1
"We are extremely grateful to the Government of Alberta for making RADICAVA available to those who are eligible for coverage under the Alberta Drug Benefit List program," said Atsushi Fujimoto, President, MTP-CA. "This is excellent news for the province's ALS community."
In addition to the Alberta public formulary, RADICAVA also is listed on the Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization) and the Ontario Drug Benefit Formulary (Exceptional Access Program). MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA under publicly funded drug programs.
About RADICAVA® (edaravone)
About Mitsubishi Tanabe Pharma Canada, Inc.
About Mitsubishi Tanabe Pharma America, Inc.
SOURCE Mitsubishi Tanabe Pharma Canada, Inc.